Global Overactive Bladder Drug Market - Industry Analysis Size Share Growth Trends and Forecast 2024 - 2031

Global Overactive Bladder Drug Market - Industry Analysis Size Share Growth Trends and Forecast 2024 - 2031

  • SKU :
    SAC9986293
  • Published Date :
    May 31, 2024
  • Number of Pages :
    350

Product Description

The Overactive Bladder Drug market was valued at US$ xx in 2023. The market for Overactive Bladder Drug is projected to grow from US$ xx million in 2024, and is projected to reach xx by 2031, at a CAGR of xx% during the forecast period. Projected and forecast revenue values are in constant U.S. dollars, unadjusted for inflation. Product values are estimated based on manufacturers' revenue.

The report offers detailed coverage of Overactive Bladder Drug industry and main market trends. The market research includes historical and forecast market data, demand, application details, price trends, and company shares of the leading Overactive Bladder Drug by geography. The report splits the market size, by volume and value, on the basis of application type and geography.

In addition to this data, the report provides insight into drivers of market demand and strategies of suppliers. Key players are profiled, and their market shares in the global Overactive Bladder Drug market are discussed.

The market is segmented by types: 
    Anticholinergics
    Solifenacin
    Oxybutynin
    Darifenacin
    Fesoterodine
    Tolterodine
    Trospium
    Others

It can be also divided by applications:
    Idiopathic Bladder Overactivity
    Neurogenic Bladder Overactivity

And this report covers the historical situation, present status and the future prospects of the global Overactive Bladder Drug market for 2021-2031. In this report, we analyze global market from 5 geographies: Asia-Pacific, Europe, North America, Middle East & Africa, South America.

Finally, the report provides detailed profile and data information analysis of leading company.
    Astellas Pharma, Inc. (Japan)
    Pfizer, Inc. (U.S.)
    Teva Pharmaceutical Industries Limited (Israel)
    Allergan, Plc (Ireland)
    Medtronic plc (Ireland)
    Mylan N.V. (U.S.)
    Endo International plc (Ireland)
    Hisamitsu Pharmaceutical Co., Inc. (Japan)
    Sanofi (France)
    Apotex, Inc. (Canada)
    Cogentix Medical, Inc. (U.S.)
    Aurobindo Pharma Limited (India)

Report Includes:
- xx data tables and xx additional tables
- An overview of global Overactive Bladder Drug market
- An detailed key players analysis across regions
- Analyses of global market trends, with historical data, estimates for 2024 and projections of compound annual growth rates (CAGRs) through 2031
- Insights into regulatory and environmental developments
- Information on the supply and demand scenario and evaluation of technological and investment opportunities in the Overactive Bladder Drug market
- Profiles of major players in the industry, including     Astellas Pharma, Inc. (Japan),     Pfizer, Inc. (U.S.),     Teva Pharmaceutical Industries Limited (Israel),     Allergan, Plc (Ireland),     Medtronic plc (Ireland).....

Research objectives
    To study and analyze the global Overactive Bladder Drug consumption (value & volume) by key regions/countries, product type and application, history data from 2019 to 2021, and Forecast to 2031.
    To understand the structure of Overactive Bladder Drug market by identifying its various subsegments.
    Focuses on the key global Overactive Bladder Drug manufacturers, to define, describe and analyze the sales volume, value, market share, market competition landscape, Porter's five forces analysis, SWOT analysis and development plans in next few years.
    To analyze the Overactive Bladder Drug with respect to individual growth trends, future prospects, and their contribution to the total market.
    To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
    To project the consumption of Overactive Bladder Drug submarkets, with respect to key regions (along with their respective key countries).
    To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
    To strategically profile the key players and comprehensively analyze their growth strategies.

Table of Content 

Table of Contents

Global Overactive Bladder Drug Market Report 2024, Forecast to 2031

1 Scope of the Study
    1.1 Overactive Bladder Drug Introduction
    1.2 Research Programs
    1.3 Analysis of Macroeconomic Indicators
    1.4 Years Considered
    1.5 Methodology
    1.6 Data Source
    1.7 Research Objectives

2 Overactive Bladder Drug Industry Overview
    2.1 Global Overactive Bladder Drug Market Size (Million USD) Comparison by Regions (2024-2031)
        2.1.1 Overactive Bladder Drug Global Import Market Analysis
        2.1.2 Overactive Bladder Drug Global Export Market Analysis
        2.1.3 Overactive Bladder Drug Global Main Region Market Analysis
    2.2 Market Analysis by Type
        2.2.1 Anticholinergics
        2.2.2 Solifenacin
        2.2.3 Oxybutynin
        2.2.4 Darifenacin
        2.2.5 Fesoterodine
        2.2.6 Tolterodine
        2.2.7 Trospium
        2.2.8 Others
    2.3 Market Analysis by Application
        2.3.1 Idiopathic Bladder Overactivity
        2.3.2 Neurogenic Bladder Overactivity
    2.4 Global Overactive Bladder Drug Revenue, Sales and Market Share by Manufacturer
        2.4.1 Global Overactive Bladder Drug Sales and Market Share by Manufacturer (2019-2023)
        2.4.2 Global Overactive Bladder Drug Revenue and Market Share by Manufacturer (2019-2023)
        2.4.3 Global Overactive Bladder Drug Industry Concentration Ratio (CR5 and HHI)
        2.4.4 Top 5 Overactive Bladder Drug Manufacturer Market Share
        2.4.5 Top 10 Overactive Bladder Drug Manufacturer Market Share
        2.4.6 Date of Key Manufacturers Enter into Overactive Bladder Drug Market
        2.4.7 Key Manufacturers Overactive Bladder Drug Product Offered
        2.4.8 Mergers & Acquisitions Planning
    2.5 Overactive Bladder Drug Historical Development Overview
    2.6 Market Dynamics
        2.6.1 Market Opportunities
        2.6.2 Market Risk
        2.6.3 Market Driving Force
        2.6.4 Porter's Five Forces Analysis
    2.7 Coronavirus Disease 2019 (Covid-19): Overactive Bladder Drug Industry Impact
        2.7.1 How the Covid-19 is Affecting the Overactive Bladder Drug Industry
        2.7.2 Overactive Bladder Drug Business Impact Assessment - Covid-19
        2.7.3 Market Trends and Overactive Bladder Drug Potential Opportunities in the COVID-19 Landscape
        2.7.4 Measures / Proposal against Covid-19

3 Upstream and Downstream Market Analysis
    3.1 Upstream Analysis
        3.1.1 Macro Analysis of Upstream Markets
        3.1.2 Key Players in Upstream Markets
        3.1.3 Upstream Market Trend Analysis
        3.1.4 Overactive Bladder Drug Manufacturing Cost Analysis
    3.2 Downstream Market Analysis
        3.2.1 Macro Analysis of Down Markets
        3.2.2 Key Players in Down Markets
        3.2.3 Downstream Market Trend Analysis
        3.2.4 Sales Channel, Distributors, Traders and Dealers

4 Global Overactive Bladder Drug Market Size Categorized by Regions
    4.1 Global Overactive Bladder Drug Revenue, Sales and Market Share by Regions
        4.1.1 Global Overactive Bladder Drug Sales and Market Share by Regions (2019-2023)
        4.1.2 Global Overactive Bladder Drug Revenue and Market Share by Regions (2019-2023)
    4.2 Europe Overactive Bladder Drug Sales and Growth Rate (2019-2023)
    4.3 APAC Overactive Bladder Drug Sales and Growth Rate (2019-2023)
    4.4 North America Overactive Bladder Drug Sales and Growth Rate (2019-2023)
    4.5 South America Overactive Bladder Drug Sales and Growth Rate (2019-2023)
    4.6 Middle East & Africa Overactive Bladder Drug Sales and Growth Rate (2019-2023)

5 Europe Overactive Bladder Drug Market Size Categorized by Countries
    5.1 Europe Overactive Bladder Drug Sales, Revenue and Market Share by Countries
        5.1.1 Europe Overactive Bladder Drug Sales by Countries (2019-2023)
        5.1.2 Europe Overactive Bladder Drug Revenue by Countries (2019-2023)
        5.1.3 Germany Overactive Bladder Drug Sales and Growth Rate (2019-2023)
        5.1.4 UK Overactive Bladder Drug Sales and Growth Rate (2019-2023)
        5.1.5 France Overactive Bladder Drug Sales and Growth Rate (2019-2023)
        5.1.6 Russia Overactive Bladder Drug Sales and Growth Rate (2019-2023)
        5.1.7 Italy Overactive Bladder Drug Sales and Growth Rate (2019-2023)
        5.1.8 Spain Overactive Bladder Drug Sales and Growth Rate (2019-2023)
    5.2 Europe Overactive Bladder Drug Revenue (Value) by Manufacturers (2019-2023)
    5.3 Europe Overactive Bladder Drug Sales, Revenue and Market Share by Type (2019-2023)
        5.3.1 Europe Overactive Bladder Drug Sales Market Share by Type (2019-2023)
        5.3.2 Europe Overactive Bladder Drug Revenue and Revenue Share by Type (2019-2023)
    5.4 Europe Overactive Bladder Drug Sales Market Share by Application (2019-2023)

6 Asia-Pacific Overactive Bladder Drug Market Size Categorized by Countries
    6.1 Asia-Pacific Overactive Bladder Drug Sales, Revenue and Market Share by Countries
        6.1.1 Asia-Pacific Overactive Bladder Drug Sales by Countries (2019-2023)
        6.1.2 Asia-Pacific Overactive Bladder Drug Revenue by Countries (2019-2023)
        6.1.3 China Overactive Bladder Drug Sales and Growth Rate (2019-2023)
        6.1.4 Japan Overactive Bladder Drug Sales and Growth Rate (2019-2023)
        6.1.5 Korea Overactive Bladder Drug Sales and Growth Rate (2019-2023)
        6.1.6 India Overactive Bladder Drug Sales and Growth Rate (2019-2023)
        6.1.7 Southeast Asia Overactive Bladder Drug Sales and Growth Rate (2019-2023)
        6.1.8 Australia Overactive Bladder Drug Sales and Growth Rate (2019-2023)
    6.2 Asia-Pacific Overactive Bladder Drug Sales and Revenue (Value) by Manufacturers (2019-2023)
    6.3 Asia-Pacific Overactive Bladder Drug Sales, Revenue and Market Share by Type (2019-2023)
        6.3.1 Asia-Pacific Overactive Bladder Drug Sales Market Share by Type (2019-2023)
        6.3.2 Asia-Pacific Overactive Bladder Drug Revenue and Revenue Share by Type (2019-2023)
    6.4 Asia-Pacific Overactive Bladder Drug Sales and Market Share by Application (2019-2023)

7 North America Overactive Bladder Drug Market Size Categorized by Countries
    7.1 North America Overactive Bladder Drug Sales, Revenue and Market Share by Countries
        7.1.1 North America Overactive Bladder Drug Sales by Countries (2019-2023)
        7.1.2 North America Overactive Bladder Drug Revenue by Countries (2019-2023)
        7.1.3 United States Overactive Bladder Drug Sales and Growth Rate (2019-2023)
        7.1.4 Canada Overactive Bladder Drug Sales and Growth Rate (2019-2023)
        7.1.5 Mexico Overactive Bladder Drug Sales and Growth Rate (2019-2023)
    7.2 North America Overactive Bladder Drug Revenue (Value) by Manufacturers (2019-2023)
    7.3 North America Overactive Bladder Drug Sales, Revenue and Market Share by Type (2019-2023)
        7.3.1 North America Overactive Bladder Drug Sales Market Share by Type (2019-2023)
        7.3.2 North America Overactive Bladder Drug Revenue and Revenue Share by Type (2019-2023)
    7.4 North America Overactive Bladder Drug Sales Market Share by Application (2019-2023)

8 South America Overactive Bladder Drug Market Size Categorized by Countries
    8.1 South America Overactive Bladder Drug Sales, Revenue and Market Share by Countries
        8.1.1 South America Overactive Bladder Drug Sales by Countries (2019-2023)
        8.1.2 South America Overactive Bladder Drug Revenue by Countries (2019-2023)
        8.1.3 Brazil Overactive Bladder Drug Sales and Growth Rate (2019-2023)
    8.2 South America Overactive Bladder Drug Revenue (Value) by Manufacturers (2019-2023)
    8.3 South America Overactive Bladder Drug Sales, Revenue and Market Share by Type (2019-2023)
        8.3.1 South America Overactive Bladder Drug Sales Market Share by Type (2019-2023)
        8.3.2 South America Overactive Bladder Drug Revenue and Revenue Share by Type (2019-2023)
    8.4 South America Overactive Bladder Drug Sales Market Share by Application (2019-2023)

9 Middle East and Africa Overactive Bladder Drug Market Size Categorized by Countries
    9.1 Middle East and Africa Overactive Bladder Drug Sales, Revenue and Market Share by Countries
        9.1.1 Middle East and Africa Overactive Bladder Drug Sales by Countries (2019-2023)
        9.1.2 Middle East and Africa Overactive Bladder Drug Revenue by Countries (2019-2023)
        9.1.3 GCC Countries Overactive Bladder Drug Sales and Growth Rate (2019-2023)
        9.1.4 Turkey Overactive Bladder Drug Sales and Growth Rate (2019-2023)
        9.1.5 Egypt Overactive Bladder Drug Sales and Growth Rate (2019-2023)
        9.1.6 South Africa Overactive Bladder Drug Sales and Growth Rate (2019-2023)
    9.2 Middle East and Africa Overactive Bladder Drug Revenue (Value) by Manufacturers (2019-2023)
    9.3 Middle East and Africa Overactive Bladder Drug Sales, Revenue and Market Share by Type
        9.3.1 Middle East and Africa Overactive Bladder Drug Sales Market Share by Type (2019-2023)
        9.3.2 Middle East and Africa Overactive Bladder Drug Revenue and Revenue Share by Type (2019-2023)
    9.4 Middle East and Africa Overactive Bladder Drug Sales Market Share by Application (2019-2023)

10 Global Overactive Bladder Drug Market Segment by Type
    10.1 Global Overactive Bladder Drug Revenue, Sales and Market Share by Type (2019-2023)
        10.1.1 Global Overactive Bladder Drug Sales and Market Share by Type (2019-2023)
        10.1.2 Global Overactive Bladder Drug Revenue and Market Share by Type (2019-2023)
    10.2 Anticholinergics Sales Growth Rate and Price
        10.2.1 Global Anticholinergics Sales Growth Rate (2019-2023)
        10.2.2 Global Anticholinergics Price (2019-2023)
    10.3 Solifenacin Sales Growth Rate and Price
        10.3.1 Global Solifenacin Sales Growth Rate (2019-2023)
        10.3.2 Global Solifenacin Price (2019-2023)
    10.4 Oxybutynin Sales Growth Rate and Price
        10.4.1 Global Oxybutynin Sales Growth Rate (2019-2023)
        10.4.2 Global Oxybutynin Price (2019-2023)
    10.5 Darifenacin Sales Growth Rate and Price
        10.5.1 Global Darifenacin Sales Growth Rate (2019-2023)
        10.5.2 Global Darifenacin Price (2019-2023)
    10.6 Fesoterodine Sales Growth Rate and Price
        10.6.1 Global Fesoterodine Sales Growth Rate (2019-2023)
        10.6.2 Global Fesoterodine Price (2019-2023)
    10.7 Tolterodine Sales Growth Rate and Price
        10.7.1 Global Tolterodine Sales Growth Rate (2019-2023)
        10.7.2 Global Tolterodine Price (2019-2023)
    10.8 Trospium Sales Growth Rate and Price
        10.8.1 Global Trospium Sales Growth Rate (2019-2023)
        10.8.2 Global Trospium Price (2019-2023)
    10.9 Others Sales Growth Rate and Price
        10.9.1 Global Others Sales Growth Rate (2019-2023)
        10.9.2 Global Others Price (2019-2023)

11 Global Overactive Bladder Drug Market Segment by Application
    11.1 Global Overactive Bladder DrugSales Market Share by Application (2019-2023)
    11.2 Idiopathic Bladder Overactivity Sales Growth Rate (2019-2023)
    11.3 Neurogenic Bladder Overactivity Sales Growth Rate (2019-2023)

12 Market Forecast for Overactive Bladder Drug
    12.1 Global Overactive Bladder Drug Revenue, Sales and Growth Rate (2024-2031)
    12.2 Overactive Bladder Drug Market Forecast by Regions (2024-2031)
        12.2.1 Europe Overactive Bladder Drug Market Forecast (2024-2031)
        12.2.2 APAC Overactive Bladder Drug Market Forecast (2024-2031)
        12.2.3 North America Overactive Bladder Drug Market Forecast (2024-2031)
        12.2.4 South America Overactive Bladder Drug Market Forecast (2024-2031)
        12.2.5 Middle East & Africa Overactive Bladder Drug Market Forecast (2024-2031)
    12.3 Overactive Bladder Drug Market Forecast by Type (2024-2031)
        12.3.1 Global Overactive Bladder Drug Sales Forecast by Type (2024-2031)
        12.3.2 Global Overactive Bladder Drug Market Share Forecast by Type (2024-2031)
    12.4 Overactive Bladder Drug Market Forecast by Application (2024-2031)
        12.4.1 Global Overactive Bladder Drug Sales Forecast by Application (2024-2031)
        12.4.2 Global Overactive Bladder Drug Market Share Forecast by Application (2024-2031)

13 Analysis of Overactive Bladder Drug Industry Key Manufacturers
    13.1 Astellas Pharma, Inc. (Japan)
        13.1.1 Company Details
        13.1.2 Product Information
        13.1.3 Astellas Pharma, Inc. (Japan) Overactive Bladder Drug Production, Price, Cost, Gross Margin, and Revenue (2019-2023)
        13.1.4 Main Business Overview
        13.1.5 Astellas Pharma, Inc. (Japan) News
    13.2 Pfizer, Inc. (U.S.)
        13.2.1 Company Details
        13.2.2 Product Information
        13.2.3 Pfizer, Inc. (U.S.) Overactive Bladder Drug Production, Price, Cost, Gross Margin, and Revenue (2019-2023)
        13.2.4 Main Business Overview
        13.2.5 Pfizer, Inc. (U.S.) News
    13.3 Teva Pharmaceutical Industries Limited (Israel)
        13.3.1 Company Details
        13.3.2 Product Information
        13.3.3 Teva Pharmaceutical Industries Limited (Israel) Overactive Bladder Drug Production, Price, Cost, Gross Margin, and Revenue (2019-2023)
        13.3.4 Main Business Overview
        13.3.5 Teva Pharmaceutical Industries Limited (Israel) News
    13.4 Allergan, Plc (Ireland)
        13.4.1 Company Details
        13.4.2 Product Information
        13.4.3 Allergan, Plc (Ireland) Overactive Bladder Drug Production, Price, Cost, Gross Margin, and Revenue (2019-2023)
        13.4.4 Main Business Overview
        13.4.5 Allergan, Plc (Ireland) News
    13.5 Medtronic plc (Ireland)
        13.5.1 Company Details
        13.5.2 Product Information
        13.5.3 Medtronic plc (Ireland) Overactive Bladder Drug Production, Price, Cost, Gross Margin, and Revenue (2019-2023)
        13.5.4 Main Business Overview
        13.5.5 Medtronic plc (Ireland) News
    13.6 Mylan N.V. (U.S.)
        13.6.1 Company Details
        13.6.2 Product Information
        13.6.3 Mylan N.V. (U.S.) Overactive Bladder Drug Production, Price, Cost, Gross Margin, and Revenue (2019-2023)
        13.6.4 Main Business Overview
        13.6.5 Mylan N.V. (U.S.) News
    13.7 Endo International plc (Ireland)
        13.7.1 Company Details
        13.7.2 Product Information
        13.7.3 Endo International plc (Ireland) Overactive Bladder Drug Production, Price, Cost, Gross Margin, and Revenue (2019-2023)
        13.7.4 Main Business Overview
        13.7.5 Endo International plc (Ireland) News
    13.8 Hisamitsu Pharmaceutical Co., Inc. (Japan)
        13.8.1 Company Details
        13.8.2 Product Information
        13.8.3 Hisamitsu Pharmaceutical Co., Inc. (Japan) Overactive Bladder Drug Production, Price, Cost, Gross Margin, and Revenue (2019-2023)
        13.8.4 Main Business Overview
        13.8.5 Hisamitsu Pharmaceutical Co., Inc. (Japan) News
    13.9 Sanofi (France)
        13.9.1 Company Details
        13.9.2 Product Information
        13.9.3 Sanofi (France) Overactive Bladder Drug Production, Price, Cost, Gross Margin, and Revenue (2019-2023)
        13.9.4 Main Business Overview
        13.9.5 Sanofi (France) News
    13.10 Apotex, Inc. (Canada)
        13.10.1 Company Details
        13.10.2 Product Information
        13.10.3 Apotex, Inc. (Canada) Overactive Bladder Drug Production, Price, Cost, Gross Margin, and Revenue (2019-2023)
        13.10.4 Main Business Overview
        13.10.5 Apotex, Inc. (Canada) News
    13.11 Cogentix Medical, Inc. (U.S.)
        13.11.1 Company Details
        13.11.2 Product Information
        13.11.3 Cogentix Medical, Inc. (U.S.) Overactive Bladder Drug Production, Price, Cost, Gross Margin, and Revenue (2019-2023)
        13.11.4 Main Business Overview
        13.11.5 Cogentix Medical, Inc. (U.S.) News
    13.12 Aurobindo Pharma Limited (India)
        13.12.1 Company Details
        13.12.2 Product Information
        13.12.3 Aurobindo Pharma Limited (India) Overactive Bladder Drug Production, Price, Cost, Gross Margin, and Revenue (2019-2023)
        13.12.4 Main Business Overview
        13.12.5 Aurobindo Pharma Limited (India) News

14 Research Findings and Conclusion

15 Appendix

Search results for Pharmaceutical Industry

Select License Type

get a sample
Ask For Customization
Get a quote
Speak to Analyst
Buy Now

Chemical & Materials

Agriculture

Pharmaceutical

Top Rated Products